Wedbush Maintains Outperform on Climb Bio, Raises Price Target to $14
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Wedbush analyst Laura Chico maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raises the price target from $12 to $14.
Wedbush analyst Laura Chico maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raises the price target from $12 to $14.